The mRNA therapeutics have been studied since the 1970s and the currently available mRNA vaccines against COVID-19 are the culmination of decades of scientific research. The mRNA vaccines BNT162b2 and mRNA-1273 have played a key role in our global response to the COVID-19 pandemic as they have demonstrated significant advantages over conventional vaccines and have proven to be highly effective against COVID-19 associated hospitalization and severe illness in large clinical trials and studies using real-world data.
All Keywords
【저자키워드】 SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, RBD, receptor-binding domain, VOC, variants of concern, MERS-CoV, Middle East respiratory syndrome coronavirus, BMI, Body mass index, VAERS, Vaccine Adverse Event Reporting System, DNA, Deoxyribonucleic acid, FDA, Food and Drug Administration, CDC, Centers for Disease Control, COVID-19, Coronavirus disease of 2019, APCs, Antigen Presenting Cells, EUA, Emergency Use Authorization, DCs, dendritic cells, MHC, major histocompatibility complex, PAMPs, pathogen-associated molecular patterns, mRNA, messenger Ribonucleic Acid, dsRNA, double-stranded RNA, GMT, geometric mean titer, nAb, neutralizing antibodies, LNP, Liposomal nanoparticle, SAM, Self-amplifying mRNA, Ad5, Adenovirus type 5, B.1.1.7, Alpha variant, B.1.351, Beta variant, COVID-NET, COVID-19-Associated Hospitalization Surveillance Network, UTR, Untranslated regions, ACE-2, Angiotensin converting enzyme receptor, CVnCOV, CureVac, GMC, Geometric mean concentration, BAU, binding antibody units, tRNA, transfer ribonucleic acid, PRNT50, plaque reduction neutralization test, BLA, Biologics License Application, VE, Vaccine efficacy, VSD, Vaccine Safety Datalink, VA, Department of Veterans Affairs,
【저자키워드】 SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, RBD, receptor-binding domain, VOC, variants of concern, MERS-CoV, Middle East respiratory syndrome coronavirus, BMI, Body mass index, VAERS, Vaccine Adverse Event Reporting System, DNA, Deoxyribonucleic acid, FDA, Food and Drug Administration, CDC, Centers for Disease Control, COVID-19, Coronavirus disease of 2019, APCs, Antigen Presenting Cells, EUA, Emergency Use Authorization, DCs, dendritic cells, MHC, major histocompatibility complex, PAMPs, pathogen-associated molecular patterns, mRNA, messenger Ribonucleic Acid, dsRNA, double-stranded RNA, GMT, geometric mean titer, nAb, neutralizing antibodies, LNP, Liposomal nanoparticle, SAM, Self-amplifying mRNA, Ad5, Adenovirus type 5, B.1.1.7, Alpha variant, B.1.351, Beta variant, COVID-NET, COVID-19-Associated Hospitalization Surveillance Network, UTR, Untranslated regions, ACE-2, Angiotensin converting enzyme receptor, CVnCOV, CureVac, GMC, Geometric mean concentration, BAU, binding antibody units, tRNA, transfer ribonucleic acid, PRNT50, plaque reduction neutralization test, BLA, Biologics License Application, VE, Vaccine efficacy, VSD, Vaccine Safety Datalink, VA, Department of Veterans Affairs,